Photo by nci from unsplash
The identification of JAK-STAT pathway mutations in the majority of patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK inhibitors and resulted in the approval of ruxolitinib… Click to show full abstract
The identification of JAK-STAT pathway mutations in the majority of patients with myeloproliferative neoplasms (MPN) led to the clinical development of JAK inhibitors and resulted in the approval of ruxolitinib for MPN therapy. Despite this important therapeutic advancement, there are significant
Keywords:
jak inhibitor;
mathematical modeling;
alternative jak;
modeling reveals;
reveals alternative;
myeloproliferative neoplasms
Journal Title: Haematologica
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Haematologica
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!